TY - JOUR
T1 - Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants
AU - Eikelboom, J. W.
AU - Kozek-Langenecker, S.
AU - Exadaktylos, A.
AU - Batorova, A.
AU - Boda, Z.
AU - Christory, F.
AU - Gornik, I.
AU - Kėkštas, G.
AU - Kher, A.
AU - Komadina, R.
AU - Koval, O.
AU - Mitic, G.
AU - Novikova, T.
AU - Pazvanska, E.
AU - Ratobilska, S.
AU - Sütt, J.
AU - Winder, A.
AU - Zateyshchikov, D.
N1 - Publisher Copyright:
© 2017 The Author(s)
PY - 2018/4
Y1 - 2018/4
N2 - Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.
AB - Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.
KW - anticoagulants
KW - coagulation monitoring
KW - emergencies
KW - haemorrhage
KW - reversal
UR - https://www.scopus.com/pages/publications/85045918679
U2 - 10.1016/j.bja.2017.11.082
DO - 10.1016/j.bja.2017.11.082
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 29576106
AN - SCOPUS:85045918679
SN - 0007-0912
VL - 120
SP - 645
EP - 656
JO - British Journal of Anaesthesia
JF - British Journal of Anaesthesia
IS - 4
ER -